Glomerular diseases: Emerging tests and therapies for IgA nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 3, 2014, Pages 617-625

  Canetta, Pietro A ^a   Kiryluk, Krzysztof ^a   Appel, Gerald B ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILAZAPRIL; CORTICOSTEROID; FISH OIL; IMMUNOGLOBULIN A; RAMIPRIL;

ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC RISK; GLYCOSYLATION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; MOLECULAR MIMICRY; OXIDATIVE STRESS; PROGNOSIS; PROTEOMICS; RISK FACTOR; SURVIVAL RATE; TONSILLECTOMY;

AUTOANTIBODIES; BIOPSY; GENETIC MARKERS; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; TONSILLECTOMY; TREATMENT OUTCOME;

EID: 84896889865     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07260713     Document Type: Article

References (57)

1. Berger J, Hinglais N: [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris) 74: 694-695, 1968.
2. D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64: 709-727, 1987.
3. Woo KT, Chan CM, Chin YM, Choong HL, Tan HK, Foo M, Anantharaman V, Lee GS, Chiang GS, Tan PH, Lim CH, Tan CC, Lee E, Tan HB, Fook-Chong S, Lau YK, Wong KS: Global evolutionary trend of the prevalence of primary glomerulonephritis over the past three decades. Nephron Clin Pract 116: c337-c346, 2010.
4. McGrogan A, Franssen CF, de Vries CS: The incidence of primary glomerulonephritis worldwide: A systematic review of the literature. Nephrol Dial Transplant 26: 414-430, 2011.
5. Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG: Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8: e1002765, 2012.
6. Varis J, Rantala I, Pasternack A, Oksa H, Jäntti M, Paunu ES, Pirhonen R: Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol 46: 607-610, 1993.
7. D'Amico G: Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24: 179-196, 2004.
8. Knoop T, Vikse BE, Svarstad E, Leh S, Reisæter AV, Bjørneklett R: Mortality in patients with IgA nephropathy [published online ahead of print June 21, 2013]. Am J Kidney Dis doi: 10.1053/ j.ajkd.2013.04.019.
9. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J: An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 81: 833-843, 2012.
10. Lai KN: Pathogenesis of IgA nephropathy. Nat Rev Nephrol 8: 275-283, 2012.
11. Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, Novak L, Matousovic K, Novak J: IgA nephropathy: Molecular mechanisms of the disease. Annu Rev Pathol 8: 217-240, 2013.
12. Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J: Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104: 73-81, 1999.
13. Ji S, Liu M, Chen J, Yin L, Sha G, Chen H, Liu Z, Li L: The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation. Clin Transplant 18: 536-540, 2004.
14. Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J: Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71: 1148- 1154, 2007.
15. Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, Shinzato T, Kobayashi Y, Maeda K: Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 59: 1077-1085, 2001.
16. Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, Mestecky J, Novak J, Julian BA: Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19: 1008-1014, 2008.
17. Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ: Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch- Schö nlein purpura nephritis. Kidney Int 80: 79-87, 2011.
18. Zwirner J, Burg M, Schulze M, Brunkhorst R, Götze O, Koch KM, Floege J: Activated complement C3: A potentially novel predictor of progressive IgA nephropathy. Kidney Int 51: 1257-1264, 1997.
19. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int 76: 546-556, 2009.
20. Donadio JV, Grande JP: IgA nephropathy. NEngl J Med 347: 738-748, 2002.
21. Pouria S, Barratt J: Secondary IgA nephropathy. Semin Nephrol 28: 27-37, 2008.
22. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, Hunley TE, Hladunewich MA, Julian BA, Fervenza FC, Cattran DC: Validation of the Oxford classification of IgA nephropathy. Kidney Int 80: 310-317, 2011.
23. Kang SH, Choi SR, Park HS, Lee JY, Sun IO, Hwang HS, Chung BH, Park CW, Yang CW, Kim YS, Choi YJ, Choi BS: The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant 27: 252-258, 2012.
24. Nishitani Y, Iwano M, Yamaguchi Y, Harada K, Nakatani K, Akai Y, Nishino T, Shiiki H, Kanauchi M, Saito Y, Neilson EG: Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. Kidney Int 68: 1078-1085, 2005.
25. Harada K, Akai Y, Yamaguchi Y, Kimura K, Nishitani Y, Nakatani K, Iwano M, Saito Y: Prediction of corticosteroid responsiveness based on fibroblast-specific protein 1 (FSP1) in patients with IgA nephropathy. Nephrol Dial Transplant 23: 3152-3159, 2008.
26. Du R, Zhao L, Xia L, Liu L, Sun W, Zhao A, Yu Y, Han H, Sun S: Association of URG11 and Twist with clinical pathological characteristics and prognosis in patients with IgA nephropathy [published online ahead of print July 4, 2013]. Nephrol Dial Transplant doi: 10.1093/ndt/gft252.
27. Tsuboi N, Kawamura T, Koike K, Okonogi H, Hirano K, Hamaguchi A, Miyazaki Y, Ogura M, Joh K, Utsunomiya Y, Hosoya T:Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy. Clin J Am Soc Nephrol 5: 39-44, 2010.
28. Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis R; Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177-3183, 2007.
29. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L: Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22: 752-761, 2011.
30. Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, Ren H, Pan X, Chen X, Zhang W, Li X, Shi H, Li Y, Gharavi AG, Chen N: Predicting progression of IgAnephropathy:Newclinical progression risk score. PLoS ONE 7: e38904, 2012.
31. Kiryluk K, Fassel DA: IgA Nephropathy Progression Calculator, New York Columbia University, 2012.
32. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP: Genomewide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43: 321-327, 2011.
33. Yu XQ, Li M, Zhang H, Low HQ, Wei X, Wang JQ, Sun LD, Sim KS, Li Y, Foo JN, Wang W, Li ZJ, Yin XY, Tang XQ, Fan L, Chen J, Li RS, Wan JX, Liu ZS, Lou TQ, Zhu L, Huang XJ, Zhang XJ, Liu ZH, Liu JJ: A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 44: 178-182, 2012.
34. Tan K, Chen J, Li W, Chen Y, Sui W, Zhang Y, Dai Y: Genome-wide analysis of microRNAs expression profiling in patients with primary IgA nephropathy. Genome 56: 161-169, 2013.
35. Lau KK, Wyatt RJ, Moldoveanu Z, Tomana M, Julian BA, Hogg RJ, Lee JY, Huang WQ, Mestecky J, Novak J: Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol 22: 2067-2072, 2007.
36. Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, Gharavi AG, Novak J, Zhang H: The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82: 790-796, 2012.
37. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J: Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23: 1579-1587, 2012.
38. Camilla R, Suzuki H, Daprà V, Loiacono E, Peruzzi L, Amore A, Ghiggeri GM, Mazzucco G, Scolari F, Gharavi AG, Appel GB, Troyanov S, Novak J, Julian BA, Coppo R: Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 6: 1903-1911, 2011.
39. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H: Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 67: 2313-2320, 2005.
40. Wu J, Wang N, Wang J, Xie Y, Li Y, Liang T, Wang J, Yin Z, He K, Chen X: Identification of a uromodulin fragment for diagnosis of IgA nephropathy. Rapid Commun Mass Spectrom 24: 1971-1978, 2010.
41. Obara T, Mizoguchi S, Shimozuru Y, Sato T, Hotta O: The complex of immunoglobulin A and uromodulin as a diagnostic marker for immunoglobulin Anephropathy. Clin Exp Nephrol 16: 713-721, 2012.
42. Kidney Disease Improving Global Outcomes (KDIGO) GlomerulonephritisWork Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2: 139-274, 2012.
43. Praga M, Gutiérrez E, González E, Morales E, Hernández E: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14: 1578-1583, 2003.
44. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G: Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19: 999-1007, 2008.
45. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. AmJ KidneyDis 41: 565-570, 2003.
46. Rasche FM, Schwarz A, Keller F: Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 51: 147-152, 1999.
47. Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, Suzuki Y, Akazawa K, Shimada H, Arakawa M, Gejyo F: The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 63: 1861-1867, 2003.
48. Maeda I, Hayashi T, Sato KK, Shibata MO, Hamada M, Kishida M, Kitabayashi C, Morikawa T, Okada N, Okumura M, Konishi M, Konishi Y, Endo G, Imanishi M: Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transplant 27: 2806-2813, 2012.
49. Donadio JV, Grande JP: The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 24: 225-243, 2004.
50. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC; Mayo Nephrology Collaborative Group: The long-termoutcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol 10: 1772-1777, 1999.
51. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163, 2004.
52. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H: Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 53: 26-32, 2009.
53. Manno C, Torres DD, Rossini M, Pesce F, Schena FP: Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24: 3694-3701, 2009.
54. Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F: Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21: 1783-1790, 2010.
55. Ballardie FW, Roberts IS: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J AmSoc Nephrol 13: 142-148, 2002.
56. Tumlin JA, Lohavichan V, Hennigar R: Crescentic, proliferative IgA nephropathy: Clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 18: 1321-1329, 2003.
57. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G: Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant 20: 2139-2145, 2005